NeoGenomics Exceeds Q1 Revenue Estimates with $187M, Posts $9M Adjusted EBITDA
NEO sits 91% above its 52-week low of $4.72.
Summary
NeoGenomics reported first-quarter revenue of $187 million, surpassing IBES estimates of $184.5 million. The company also posted $9 million in adjusted EBITDA and $1.4 million in adjusted net income, though it recorded a net loss of $17 million for the quarter. This Q1 performance follows the company's 2025 annual 10-K filing in February, which noted double-digit revenue growth but also a significant increase in net loss. The revenue beat is a positive indicator for top-line growth, suggesting stronger demand than anticipated. However, the continued net loss, despite positive adjusted metrics, will likely keep investor focus on the path to sustained profitability. Traders will be watching the market's reaction to the mixed results, particularly the revenue outperformance.
At the time of this announcement, NEO was trading at $9.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $4.72 to $13.74. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Reuters.